Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Accumulated Expenses (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Accumulated Expenses for 3 consecutive years, with $9.6 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 98.72% to $9.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.6 million through Dec 2025, up 98.72% year-over-year, with the annual reading at $9.6 million for FY2025, 98.72% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $9.6 million at Artiva Biotherapeutics, up from $5.6 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $9.6 million in Q4 2025, with the low at $2.5 million in Q1 2025.
  • Average Accumulated Expenses over 3 years is $5.9 million, with a median of $5.7 million recorded in 2025.
  • The sharpest move saw Accumulated Expenses tumbled 39.74% in 2024, then skyrocketed 98.72% in 2025.
  • Over 3 years, Accumulated Expenses stood at $8.0 million in 2023, then crashed by 39.74% to $4.8 million in 2024, then surged by 98.72% to $9.6 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $9.6 million, $5.6 million, and $5.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.